Valeant Pharmaceuticals
Valeant Pharmaceuticals International, Inc. was a multinational specialty pharmaceutical company, known for its focus on dermatology, gastrointestinal disorders, and eye health (primarily through its Bausch + Lomb division). The company gained significant notoriety for its aggressive acquisition strategy, often followed by substantial price increases on acquired drugs, and faced extensive scrutiny over its business practices, including accounting methods and relationships with specialty pharmacies. These controversies led to a dramatic decline in its stock value and reputation, ultimately prompting a corporate rebranding.
About Us
- Founded in 1994, Valeant Pharmaceuticals initially focused on neurology and dermatology. - Under CEO Michael Pearson from 2008, the company pursued an aggressive 'buy-and-build' strategy, acquiring over 100 companies and growing rapidly, though this approach was criticized for relying on drug price hikes and minimal R&D. - From late 2015, Valeant faced multiple scandals concerning drug pricing and alleged accounting irregularities, leading to investigations, executive changes, and significant restructuring. - In July 2018, Valeant Pharmaceuticals rebranded as Bausch Health Companies Inc. - to signify a new strategic direction and distance itself from its controversial past.
Vision
Valeant's strategic vision aimed to be a rapidly growing and highly profitable specialty pharmaceutical company globally. This was primarily pursued by leveraging a highly efficient acquisition and commercialization model to maximize market share and financial performance across various therapeutic areas, often at the expense of traditional in-house drug development and research.
Mission
While Valeant Pharmaceuticals did not maintain a consistent, publicly articulated mission statement during its most scrutinized period, its operational focus was centered on building a leading global specialty pharmaceutical enterprise. This was pursued primarily by acquiring and integrating valuable assets, optimizing operational efficiencies, and delivering significant financial returns to shareholders through aggressive portfolio management and commercialization strategies, rather than traditional drug discovery.
Culture
- Valeant's corporate culture, particularly during its aggressive expansion phase, was widely described as highly performance-driven, financially oriented, and intensely focused on mergers, acquisitions, and stringent cost-cutting. - There was a strong emphasis on achieving ambitious financial targets and rapidly integrating acquired entities, often with lean staffing models. - This approach contrasted sharply with traditional pharmaceutical industry cultures, which typically prioritize long-term research and development. - The culture was criticized for potentially fostering an environment where short-term financial gains overshadowed patient considerations and long-term scientific innovation.
Specialties & Industries
Open Positions
No open positions at the moment
Check back later for new opportunities